Patents Assigned to RADIUS PHARMACEUTICALS, INC.
-
Patent number: 11911361Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.Type: GrantFiled: September 22, 2017Date of Patent: February 27, 2024Assignee: RADIUS PHARMACEUTICALS, INC.Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
-
Patent number: 11857518Abstract: Disclosed herein are methods of treating one or more tumors by administering to the subject a therapeutically effective amount of a combination of RAD1901 or solvates (e.g., hydrate) or salts thereof and one or more second therapeutic agent(s) (e.g., everolimus). The cancer is an estrogen-dependent cancer, such as breast cancer, ovarian cancer, colon cancer, endometrial cancer, or prostate cancer.Type: GrantFiled: October 25, 2021Date of Patent: January 2, 2024Assignee: RADIUS PHARMACEUTICALS, INC.Inventor: Gary Hattersley
-
Patent number: 11819480Abstract: Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer or a mutant estrogen receptor alpha positive cancer. The methods entail administering to the subject a therapeutically effective amount of RAD1901 having the structure: or a salt or solvate thereof.Type: GrantFiled: August 4, 2020Date of Patent: November 21, 2023Assignee: RADIUS PHARMACEUTICALS, INC.Inventors: Fiona Garner, Gary Hattersley
-
Patent number: 11708318Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.Type: GrantFiled: September 14, 2021Date of Patent: July 25, 2023Assignee: RADIUS PHARMACEUTICALS, INC.Inventors: Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
-
Patent number: 11643385Abstract: A solid form of RAD1901-2HCl having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2?±0.2 degrees 2?, and compositions, methods, and processes thereof.Type: GrantFiled: July 3, 2019Date of Patent: May 9, 2023Assignee: Radius Pharmaceuticals, Inc.Inventors: Michael Paul Cruskie, Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
-
Publication number: 20220280446Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.Type: ApplicationFiled: February 18, 2022Publication date: September 8, 2022Applicant: RADIUS PHARMACEUTICALS, INC.Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
-
Patent number: 11413258Abstract: Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and RAD1901.Type: GrantFiled: September 24, 2019Date of Patent: August 16, 2022Assignee: Radius Pharmaceuticals, Inc.Inventor: Gary Hattersley
-
Patent number: 11384068Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: January 22, 2019Date of Patent: July 12, 2022Assignee: Radius Pharmaceuticals, Inc.Inventor: Chris Miller
-
Publication number: 20220184215Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.Type: ApplicationFiled: December 22, 2021Publication date: June 16, 2022Applicant: RADIUS PHARMACEUTICALS, INC.Inventors: Kiran Kumar VANGARA, Huaguang LI, Ningxin YAN, Hung Q. Nguyen, Venkat R. GOSKONDA
-
Patent number: 11331279Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.Type: GrantFiled: July 31, 2015Date of Patent: May 17, 2022Assignee: RADIUS PHARMACEUTICALS, INC.Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
-
Publication number: 20220125932Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.Type: ApplicationFiled: November 5, 2021Publication date: April 28, 2022Applicant: RADIUS PHARMACEUTICALS INC.Inventors: Kiran Kumar VANGARA, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
-
Publication number: 20220054450Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.Type: ApplicationFiled: November 5, 2021Publication date: February 24, 2022Applicant: RADIUS PHARMACEUTICALS, INC.Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
-
Patent number: 11224660Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.Type: GrantFiled: May 28, 2015Date of Patent: January 18, 2022Assignee: RADIUS PHARMACEUTICALS, INC.Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
-
Publication number: 20210330797Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.Type: ApplicationFiled: July 6, 2021Publication date: October 28, 2021Applicant: RADIUS PHARMACEUTICALS, INC.Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
-
Patent number: 11148996Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.Type: GrantFiled: July 6, 2020Date of Patent: October 19, 2021Assignee: Radius Pharmaceuticals, Inc.Inventors: Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
-
Patent number: 10745343Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.Type: GrantFiled: September 13, 2019Date of Patent: August 18, 2020Assignee: RADIUS PHARMACEUTICALS, INC.Inventors: Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
-
Patent number: 10385008Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.Type: GrantFiled: January 5, 2018Date of Patent: August 20, 2019Assignee: Radius Pharmaceuticals, Inc.Inventors: Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
-
Patent number: 9920044Abstract: This invention provides compounds of formula I, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.Type: GrantFiled: July 22, 2015Date of Patent: March 20, 2018Assignee: RADIUS PHARMACEUTICALS, INC.Inventor: Chris P. Miller